>>8886356 (LB)
RE: Meat package plants and Military ability to take them over
I wouldn't wish that on my brothers and sisters serving - shit jobs.
These huge plants should go away and we move back to local processing / butchering. Too many regulations for slaughterhouses as well (that benefit large operators - nothing wrong with food safety & animal welfare measures).
Baker Notable
This is great. Downloaded and digesting
There are other docs on the site that are very interesting!
https://www.mediterranee-infection.com/wp-content/uploads/2020/04/Azithro_COVID.pdf
1Azithromycinand ciprofloxacin have a chloroquine-like effect onrespiratory epithelial cellsJens F. Poschet1, ElizabethA.Perkett2,3, Graham S. Timmins4#and Vojo Deretic1,5#Departmentsof 1Molecular Genetics and Microbiology 2Pediatricsand 3 Internal Medicine, 4Pharmaceutical Sciences, and5Autophagy, Inflammation and Metabolism Center of Biomedical Research Excellence, University of New Mexico Health Science Center# Co-corresponding author
AbstractThere isinterest in the use of chloroquine/hydroxychloroquine (CQ/HCQ) and azithromycin(AZT)in COVID-19 therapy. Employingcystic fibrosis respiratory epithelial cells, herewe show that drugs AZTandciprofloxacin(CPX)act as acidotropic lipophilic weak bases and conferin vitro effectson intracellular organellessimilarto the effects of CQ. These seemingly disparate FDA-approved antimicrobialsdisplay a common property of modulating pH of endosomes and trans-Golgi network.We believe this may in part help understandthe potentially beneficial effects of CQ/HCQ and AZT in COVID-19, and that the present considerations of HCQ and AZT for clinicaltrials should be extended to CPX.
and
Conclusion
4 Please cite this work as Gautret et al. (2020) Hydroxychloroquine and azithromycin as a treatment of COVID‐19: results of an open‐label non‐randomized clinical trial. International Journal of Antimicrobial Agents – In Press 17 March 2020 – DOI : 10.1016/j.ijantimicag.2020.105949 Despite its small sample size our survey shows that hydroxychloroquine treatment is significantly associated with viral load reduction/disappearance in COVID-19 patients and its effect is reinforced by azithromycin.
https://www.mediterranee-infection.com/wp-content/uploads/2020/03/Hydroxychloroquine_final_DOI_IJAA.pdf
Conclusion for last reference:
Despite its small sample size our survey shows that hydroxychloroquine treatment is significantly associated with viral load reduction/disappearance in COVID-19 patients and its effect is reinforced by azithromycin.
YES! Some real research here anons! Excellent quality work. And these fine health workers in France know plenny about HCQ:
A recent paper reported an inhibitor effect of remdesivir (a new antiviral drug) and chloroquine (an old antimalarial drug) on the growth of SARS-CoV-2 in vitro, [8] and an early clinical trial conducted in COVID-19 Chinese patients, showed that chloroquine had a significant effect, both in terms of clinical outcome and viral clearance, when comparing to controls groups [9,10]. Chinese experts recommend that patients diagnosed as mild, moderate and severe cases of COVID-19 pneumonia and without contraindications to chloroquine, be treated with 500 mg chloroquine twice a day for ten days [11]. Hydroxychloroquine (an analogue of chloroquine) has been demonstrated to have an anti-SARS-CoV activity in vitro [12]. Hydroxychloroquine clinical safety profile is better than that of chloroquine (during long-term use) and allows higher daily dose [13] and has fewer concerns about drug-drug interactions [14]. Our team has a very comprehensive experience in successfully treating patients with chronic diseases due to intracellular bacteria (Q fever due to Coxiella burnetii and Whipple’s disease due to Tropheryma whipplei) with long-term hydroxychloroquine treatment (600 mg/day for 12 to 18 months) since more than 20 years.[15,16] We therefore started to conduct a clinical trial aiming at assessing the effect of hydroxychloroquine on SARS-CoV-2-infected patients after approval by the French Ministry of Health. In this report we describe our early results, focusing on virological data in patients receiving hydroxychloroquine as compared to a control group.
Also, note in the table, the "time between onset of symptoms and treatment start".
How much better would it be if done faster than 6 days??
How many days for the VA study??
Pussy-hat version - noice!
You go anon - noice rant!
second on minibun